NasdaqGM:XENEBiotechs
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds
Xenon Pharmaceuticals (NasdaqGM:XENE) is back in focus after reporting a second quarter net loss of US$110.74 million and preparing to present at Stifel’s 2026 Biotech Summer Summit on August 10 in Newport.
See our latest analysis for Xenon Pharmaceuticals.
Despite the wider loss, Xenon Pharmaceuticals shares have cooled in the last month with a 1-month share price return of down 8.66% and a 7-day move of down 1.59%. However, the 90-day share price return of 16.09% and 1-year total...